Diabetes

Since aldosterone has become a pivotal hypertensive hormone, screening with or without confirmation should be part of primary care practice. Here's a straightforward approach.

Attention to a few easily obtained details can prevent serious sequelae in patients with T2 diabetes complicated by cardiovascular and renal disease.

This study demonstrated that in patients with type 2 diabetes mellitus, use of β-blockers was associated with an increased risk for cardiovascular events and severe hypoglycemia. Details here.

Here: a quick look at newly approved agents for primary care that will soon be coming your way.

A new meta-analysis finds that routine intake of artificial sweeteners is linked to weight gain and metabolic dysfunction. Wait, what? 

Apps to guide osteoporosis treatment, insulin management, endocrine emergencies, plus ADA and Endo Society standards of care, at-a-glance.

A first-of-its-kind study reports an association between T1DM and AF, and between glycemic control and AF. Plus, there are gender differences.

Chronic renal disease is common in primary care settings and so are its comorbidities. In brief here, 5 apps you might want at hand.

Providers may now be paid up to $785 (increased from $450) for each patient who loses 5% of their body weight.

Study: each gain of 5 kg was linked to a 17% drop in odds of healthy aging. A powerful message for young patients.

Results from studies on the asthma-diabetes connection are inconsistent. A novel analysis may help clarify directionality.

Can you identify the cause of the hyperpigmented umbilicated lesions seen bilaterally on the patient's extremities and on her back?

Studies summarized in this slide show focus on fine-tuning insulin-containing regimens to enhance glucose control and avoid variability.

Test your knowledge of the products of climate change and the health effects they may have.

Glycemic variability fuels hypoglycemia but in one study from ADA 2017 is found to actually help predict hypoglycemic events.

Cardiovascular risk/benefit profiles of pioglitazone and the SGLT2 inhibitor class are summarized, based on reports at ADA 2017.

A1C vs FPG to diagnose prediabetes; prediabetes and CHF; and how much weight loss is too much? Reports from ADA 2017.

Insulin degludec vs glargine--which costs less per anum and why? We summarize this study and 2 other direct insulin comparisons reported at ADA 2017.

When to start screening for B12 deficiency in your diabetes patients taking metformin? We review a dose-response diet study plus 2 others on oral drugs.

Increases in diabetes, insomnia, and skin cancer are just 3 of the hazardous trends identified in recent research. More findings in our slide show.

Test your knowledge of the safety events that have occurred involving FDA-approved drugs since the turn of the century.

Try these 10 questions and see what you've learned during this month's special report on the nuts-and-bolts of T2DM for PCPs.

A how-to overview of how to advance therapy for hyperglycemia and ASCVD risk factors in patients with T2DM.

Self-monitoring of blood glucose is critical for all patients with T2DM and their physicians.The numbers help modify behavior and Rx.

Seven top diabetes apps for PCPs include insulin calculators, Rx algorithms, comorbidity support, and patient tracking tools.